NCT07251998

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 172 (estimated)
• Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	ICP-332 Tablets	ICP-332 will be administered as tablet for 12 weeks
DRUG	ICP-332 Tablets	ICP-332 will be administered as tablet for 12 weeks
DRUG	ICP-332 Tablets	ICP-332 will be administered as tablet for 12 weeks
OTHER	ICP-332 Placebo Tablets	Placebo will be administered as tablet for 12 weeks

Timeline

• Start date: 2025-12-22
• Primary completion: 2026-10-01
• Completion: 2027-05-01
• First posted: 2025-11-26
• Last updated: 2025-12-31

Locations

1 site across 1 country: China